Amneal Pharmaceuticals’ first quarter results were met with a negative reaction from the market, reflecting revenue that trailed Wall Street forecasts despite year-on-year growth. Management attributed the performance to strong momentum in its Specialty segment, particularly the launch of CREXONT for Parkinson’s disease, as well as ongoing expansion in injectables and biosimilars. CEO Chirag Patel highlighted, “CREXONT has made me feel and move tremendously better compared to RYTARY,” referencing patient feedback and increased market access as key drivers. The quarter also benefited from new product launches and operational efficiencies, which supported significant improvement in operating margin.

Is now the time to buy AMRX? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Amneal’s Q1 Earnings Call

• David Amsellem (Piper Sandler) asked about biosimilars’ 2025 revenue contribution and timing of vertical integration. CEO Chirag Patel confirmed expectations for $150-160 million in biosimilars revenue, with full vertical integration targeted by next year.

• Amsellem (Piper Sandler) also questioned injectable product focus. Co-CEO Chintu Patel explained that Amneal is investing equally in both complex injectables and high-volume shortage products, with new launches planned for both areas.

• Les Sulewski (Truist Securities) inquired about AvKARE’s exposure to government spending cuts and FDA approval delays. CEO Chirag Patel noted that AvKARE is seeing volume growth in government channels and has not experienced FDA delays.

• Sulewski (Truist Securities) also asked about CREXONT’s international rollout. Chirag Patel outlined progress in partnering for Canada, Latin America, Europe, Southeast Asia, and a direct launch in India, with ongoing discussions in China and Japan.

• Chris Schott (JPMorgan) probed how Amneal would respond to potential pharmaceutical tariffs. Chirag Patel highlighted available U.S. manufacturing capacity and the likelihood of cost-sharing with large customers if tariffs are enacted.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the continued adoption and insurance coverage expansion of CREXONT, (2) execution and regulatory progress for new specialty and injectable launches, and (3) developments in the biosimilars pipeline and vertical integration strategy. Progress in constructing GLP-1 manufacturing facilities and clarity on tariff impacts will also be key areas of focus.

Amneal currently trades at $8.13, up from $7.74 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.